Scientific Programme & Abstracts from the International Meeting in Pediatric Endocrinology (IMPE)
IMPE Abstracts (2023) 96 P151

1Hospital de Niños Pedro de Elizalde, Buenos Aires, Argentina. 2Hospital General de Agudos Carlos G Durand, Buenos Aires, Argentina. 3Hospital de Niños Sor Maria Ludovica, La Plata, Argentina. 4Hospital Nacional Profesor Alejandro Posadas, El Palomar, Argentina


Introduction: Transgender and gender–diverse (TGD) individuals do not fully identify with the gender assigned at birth. Argentina has approved in 2012 a pioneer gender identity law (N° 26.743) which depathologize this condition and guarantees access to medical care of TGD individuals. In recent years, there has been a significant increase in the number of youth seeking gender-affirming medical interventions leading to the creation of multidisciplinary care teams in order to respond to the growing demand.

Aim: to describe different aspects of the largest Argentinian TGD children and adolescents cohort

Materials and methods: retrospective, observational, multicenter cohort study, including 312 TGD children and adolescents admitted at 4 Hospitals from Buenos Aires, Argentina from 2014 to 2022.

Results: 247 transmale (TM) and 65 transfemale (TF) were included (ratio TM:TF 3.8:1). Mean age for TM was 14.7 +/- 2.26 and for TF 14.7+/-2.9 years. Mean chronological age at first perception was 8.8 +/-3.3 years for TM and 8.6 +/-4.2 for TF, mean chronological age for social transition was 12.6 +/-2.3 for TM and 12.4 +/-4 years for TF. Nutritional aspect: 40.96% (n=93) of TM and 30% (n=18) of TF were obese or had overweight; 6.5% (n=16) of TM and 3% (n=2) of TF had eating disorders; 25 hydroxivitamin D deficiency was found in 88.66% (n=203) of the total population. Psychological comorbidities including anxiety, depression, panic attacks and psychosis among TGD were present in 27.5% (n=86). Mean Basal BMD Z score was 0.13 +/- 0.97 in TM and -1.05 +/- 0.97 in TF. GnRh analogs were started in 94 TM at a mean age of 13.9 +/-2 years and in 33 TF at 15.7 +/-1.75. Gender-affirming hormone treatment was started in 84 TM at a mean age of 16.3 +/-1.17 and in 29 TF at 16.6 +/-0.99. Progestagen was used in 7.3% (n 18) and breast surgery was performed in 8% (n=20) of TM.

Conclusions: Among individuals of our cohort we found a higher prevalence of Transmen and a large percentage of obesity, overweight, vitamin D deficiency and psychological comorbidities. These findings support the fact that the optimal model of care for TGD children and adolescents involves a coordinated multidisciplinary team approach. To our knowledge this is the largest Argentinian cohort study describing different aspects of TGD children and adolescents.

Volume 96

IMPE 2023

Buenos Aires, Argentina
04 Mar 2023 - 07 Mar 2023

International Meeting in Pediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.